• Home
  • Biopharma
  • Will Veeva and Amgen’s $50 Billion Industry Push Set a New Global Standard for Technology-Driven Clinical Trials?
Image

Will Veeva and Amgen’s $50 Billion Industry Push Set a New Global Standard for Technology-Driven Clinical Trials?

Key Highlights:

  • Veeva Systems partners with Amgen to deploy its end-to-end Clinical Platform across global trials.
  • Collaboration aims to accelerate new medicine development by streamlining trial operations with advanced digital tools.
  • Marks a pivotal industry shift toward technology-driven clinical trial innovation, promising faster patient access to breakthrough therapies.

Collaboration to Accelerate Clinical Development
Veeva Systems announced a landmark collaboration with Amgen to transform clinical trial execution through the adoption of the Veeva Clinical Platform. By integrating this connected ecosystem across operations, Amgen aims to identify new efficiencies, improve trial oversight, and accelerate timelines for delivering novel treatments. This collaboration highlights how technology and biotech leadership are converging to advance medicine at scale.

Digital Backbone for End-to-End Trials
The Veeva Clinical Platform offers a comprehensive suite including CTMS, EDC, CDB, RTSM, eCOA, eTMF, Site Connect, and Study Training. Together, these tools create a unified data flow that streamlines every phase of a trial, from start-up through closeout. With automated processes and standardized workflows, Amgen expects to unlock new levels of agility while reducing operational complexity across its global research footprint.

Driving Innovation With Strategic Business Consulting
Beyond technology, Veeva Business Consulting will guide Amgen in implementation and change management, ensuring seamless integration into existing operations. This strategic support is expected to maximize value realization, enabling Amgen to deliver faster, smarter, and more patient-focused trials. The partnership reflects a shared vision to combine cutting-edge platforms with expert-driven transformation.

Company Commitments to Patients and Industry
For Amgen, the collaboration reinforces its mission of accelerating the development of medicines for serious diseases through innovation and scale. For Veeva, it further validates its role as the digital backbone of modern life sciences, trusted by more than 1,500 biopharma customers worldwide. Together, the two companies are setting a new industry benchmark for how advanced platforms can reshape the clinical trial ecosystem and ensure patients benefit sooner from medical breakthroughs.

About Veeva Systems
Veeva Systems (NYSE: VEEV) is a global leader in cloud-based solutions for the life sciences industry, delivering software, data, and business consulting that empower over 1,500 companies, from top biopharma to emerging biotech. As a Public Benefit Corporation, Veeva is committed to balancing customer success with stakeholder value, innovation, and industry transformation.

About Amgen
Amgen is one of the world’s leading biotechnology companies, focused on discovering, developing, and delivering innovative medicines that address serious diseases. With a robust pipeline and global presence, Amgen combines cutting-edge science with a commitment to patients, pioneering breakthroughs across oncology, immunology, and rare diseases.

Releated Posts

Will BioNTech and Pfizer’s Counterstrike Against GSK Reshape Europe’s Largest mRNA Patent War?

Key Insights GSK’s Offensive Meets Resistance GSK launched a sweeping litigation campaign in 2024, targeting BioNTech and Pfizer…

ByByAnuja SinghSep 13, 2025

Can LB Pharmaceuticals’ $285M IPO Reignite Investor Confidence in Biotech After Months of Silence?

Key Insights IPO Breaks Market Drought LB Pharmaceuticals, a CNS-focused biotech, has defied a months-long IPO drought by…

ByByAnuja SinghSep 13, 2025

Is Merck’s £1B Exit Forcing AstraZeneca, Lilly, and Sanofi to Rethink UK’s Life Sciences Future?

Key Insights Merck Triggers Domino Effect with £1B Withdrawal Merck’s decision to abandon its £1-billion London R&D facility…

ByByAnuja SinghSep 13, 2025

Will AbbVie’s Rinvoq Patent Deal Lock Out Generics Until 2037—Securing a $31B Immunology Stronghold?

Key Highlights: Patent Shield Extended Through SettlementsAbbVie has successfully resolved litigation with multiple generic challengers—including Sandoz, Aurobindo, Intas,…

ByByAnuja SinghSep 12, 2025
Scroll to Top